Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
- Revenue in USD (TTM)4.82bn
- Net income in USD1.51bn
- LocationVertex Pharmaceuticals Inc50 Northern AveBOSTON 02210-1862United StatesUSA
- Phone+1 (617) 341-6393
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|VRTX:NSQ since |
|Semma Therapeutics Inc||Announced||03 Sep 2019||03 Sep 2019Announced||58.29%||950.00m|
|Exonics Therapeutics Inc||Deal completed||06 Jun 2019||06 Jun 2019Deal completed||64.46%||1.05bn|